ScottHKaufmannMDPhD
Hematology • Rochester, MNHematologic Oncology
Consultant in Hematology Mayo Clinic Rochester, MN
Dr. Kaufmann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1985 - 1987- Johns Hopkins UniversityResidency, Internal Medicine, 1982 - 1985
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1981 - 1982
- Johns Hopkins University School of MedicineClass of 1981
Certifications & Licensure
MN State Medical License 1995 - 2025
MD State Medical License 1985 - 1994- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia Start of enrollment: 1995 Oct 01
- Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia Start of enrollment: 1999 Nov 01
- Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 2004 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents.Rocco Caggiano, Evgeniia Prokhorova, Lena Duma, Kira Schützenhofer, Raffaella Lauro
Neoplasia. 2024-11-29 - FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(): the Mayo Clinic experience.Clifford M Csizmar, Antoine N Saliba, Patricia T Greipp, Hassan Alkhateeb, Kebede H Begna
Haematologica. 2024-11-01 - Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors.Annapoorna Venkatachalam, Cristina Correia, Kevin L Peterson, Xianon Hou, Paula A Schneider
Molecular Cancer. 2024-10-07
Journal Articles
- Methylation of All BRCA1 Copies Predicts Response to the PARP Inhibitor Rucaparib in Ovarian CarcinomaScott H Kaufmann, Elizabeth M Swisher, Nature
Abstracts/Posters
- A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)Scott H. Kaufmann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic S...Scott H. Kaufmann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
The Deubiquitinase USP36 Regulates DNA Replication Stress and Confers Therapeutic Resistance Through PrimPol StabilizationNovember 25th, 2020
Grant Support
- Anticancer Drug-Induced Bh3-Only Protein.Bak InteractionsNational Cancer Institute2012
- Poisoning Of PARP And Topoisomerase I To Treat Ovarian CancerNational Cancer Institute2009–2011
- Developmental Research ProgramNational Cancer Institute2009–2011
- Role Of Proteases In Therapy-Induced ApoptosisNational Cancer Institute2006–2010
- Topoisomerase I Inhibitors In Leukemia And Solid TumorsNational Cancer Institute2004–2010
- Preclinical Evaluation Of Bcr/Abl-Directed TyrphostinsNational Cancer Institute2004–2007
- Multidisciplinary Training In Experimental HematologyNational Heart, Lung, And Blood Institute2004–2005
- Role Of Proteases In Chemotherapy Induced ApoptosisNational Cancer Institute2004–2005
- Role Of Proteases In Chemotherapy Induced ApoptosisNational Cancer Institute2002–2003
- Multidisciplinary Training In Experimental HematologyNational Heart, Lung, And Blood Institute2001–2003
- Topoisomerase I Inhibitors In Leukemia And Solid TumorsNational Cancer Institute1997–2003
- Preclinical Evaluation Of BCR/ABL Directed TyrphostinsNational Cancer Institute2000–2002
- Proteases And Chemotherapy Induced ApoptosisNational Cancer Institute1995–2001
- Novel Mechanism Of Multiple Drug ResistanceNational Cancer Institute1995–1998
- Gordon Conference On ChemotherapyNational Cancer Institute1997
- Mechanism Of Cytotoxicity Of Topoisomerase II PoisonsNational Cancer Institute1994
- Mechanism Of Cytotoxicity Of Topoisomerase II PoisonsNational Cancer Institute1992–1994
- Topoisomerase II And Drug Resistance In Acute LeukemiaNational Cancer Institute1989–1991
- Analysis Of Nonlamin Nuclear Envelope PolypeptidesNational Institute Of General Medical Sciences1985
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
